BioLineRx to Present at 2015 BIO CEO & Investor Conference in New York on February 10
A live webcast of the presentation will be available on BioLineRx's website. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.
Investors or potential partners attending the conference who wish to meet with Dr. Savitsky or Mr. Serlin should contact the BIO Partnering Team at biopartnering@bio.org.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a
In
For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store.
Source: BioLineRx
Tiberend
Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
+1-212-375-2664
jdrumm@tiberend.com
or
Andrew
Mielach
+1-212-375-2694
amielach@tiberend.com
or
BioLineRx
Tsipi
Haitovsky
Public Relations
+972-3-6240871
tsipih@netvision.net.il